

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(PCT Rule 71.1)

To:

MARTYRES, Domnic
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein
ALLEMAGNE

Eingang

19. Feb. 2025

Date of mailing
(day/month/year)

17.02.2025

Applicant's or agent's file reference
01-3543-WO-1

Global Patents

IMPORTANT NOTIFICATION

International application No.
PCT/EP2024/055766

International filing date (day/month/year)
06.03.2024

Priority date (day/month/year)
13.03.2023

Applicant
BOEHRINGER INGELHEIM INTERNATIONAL GMBH

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international
preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0

Authorized Officer

Benitez Sierra, O

Tel. +49 89 2399-5715



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 01-3543-WO-1	FOR FURTHER ACTION		See Form PCT/IPEA/416
International application No. PCT/EP2024/055766	International filing date (day/month/year) 06.03.2024	Priority date (day/month/year) 13.03.2023	
International Patent Classification (IPC) or national classification and IPC INV. A61P9/10			
Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH			
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of <u>8</u> sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: a. ☒ a total of <u>14</u> sheets, as follows: ☒ sheets of the description, claims and/or drawings which have been amended and/or sheets containing rectifications authorized by this Authority, unless those sheets were superseded or cancelled, and any accompanying letters (see Rules 46.5, 66.8, 70.16, 91.2, and Section 607 of the Administrative Instructions). ☐ sheets containing rectifications, where the decision was made by this Authority not to take them into account because they were not authorized by or notified to this Authority at the time when this Authority began to draw up this report, and any accompanying letters (Rules 66.4bis, 70.2(e), 70.16 and 91.2). ☐ superseded sheets and any accompanying letters, where this Authority either considers that the superseding sheets contain an amendment that goes beyond the disclosure in the international application as filed, or the superseding sheets were not accompanied by a letter indicating the basis for the amendments in the application as filed, as indicated in item 4 of Box No. I and the Supplemental Box (see Rule 70.16(b)). b. ☐ a separate electronic file containing a sequence listing (<i>sent to the International Bureau only</i>)			
4. This report contains indications relating to the following items: ☒ Box No. I Basis of the report ☒ Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☒ Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application			
Date of submission of the demand 11.10.2024		Date of completion of this report 17.02.2025	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0		Authorized officer Brandstetter, T Telephone No. +49 89 2399-5847	



**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2024/055766

Box No. I Basis of the report

1. With regard to the **language**, this report is based on
- ☒ the international application in the language in which it was filed
 - ☐ a translation of the international application into , which is the language of a translation furnished for the purposes of:
 - ☐ international search (under Rules 12.3(a) and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4(a))
 - ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a) and (b))
2. With regard to the **elements*** of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):

Description, Pages

1-116 as originally filed

Claims, Numbers

1-17 filed with the demand for preliminary international examination

- ☐ a sequence listing - see Supplemental Box Relating to Sequence Listing.
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since either they are considered to go beyond the disclosure as filed, or they were not accompanied by a letter indicating the basis for the amendments in the application as filed, as indicated in the Supplemental Box (Rules 70.2(c) and (c-bis)):
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
5. ☐ This report has been established:
- ☐ taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rules 66.1(d-bis) and 70.2(e)).
 - ☐ without taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91(Rules 66.4bis and 70.2(e)).

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2024/055766

6. ☒ With regard to top-up searches (Rules 66.1 *ter* and 70.2(f)):
- ☒ A top-up search was carried out by this Authority on 06.02.2025 (all discovered documents are listed in the Supplemental Box Relating to Top-up Search).
 - ☐ Additional relevant documents have been discovered during the top-up search.
 - ☐ No top-up search was carried out by this Authority because it would serve no useful purpose.
7. ☐ Supplementary international search report(s) from Authority(ies) has/have been received and taken into account in establishing this report (Rule 45bis.8(b) and (c)).

* If item 4 applies, some or all of those sheets may be marked "superseded".

Box No. II Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed (Rule 66.7(a)).
 - ☐ translation of the earlier application whose priority has been claimed (Rule 66.7(b)).
2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rule 64.1). Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.
3. Additional observations, if necessary:

see separate sheet

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	<u>1-17</u>
	No: Claims	
Inventive step (IS)	Yes: Claims	<u>1-17</u>
	No: Claims	
Industrial applicability (IA)	Yes: Claims	<u>1-17</u>
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2024/055766

Box No. VI Certain documents cited

1. Certain published documents (Rule 70.10)
and /or
2. Non-written disclosures (Rule 70.9)
see separate sheet

1 Reference is made to the following documents:

- D1 M. Jimenez-Sanchez et al., Nature Chemical Biology, 11 (5), 2015, pages 347-354, XP055479437
& M. Jimenez-Sanchez et al., "Supplementary information: Nature Chemical Biology, 11 (5), 2015, cited in the application, XP093067541
- D2 WO 2018/178384 A1 (2018-10-04), cited in the application
- D3 WO 2022/086920 A1 (2022-04-28), cited in the application
- D4 WO 2024/020517 A1 (2024-01-25)

Re Item I

Claim 1 has been restricted to compounds wherein R¹ is F based on the embodiment on page 14, lines 16-18.

Claims 2-8 correspond to original claims 2-8.

Claim 9 has been amended wherein compounds, wherein R¹ is H have been deleted.

New claim 10 lists those compounds of original claim 9 wherein R¹ is H.

Claim 11-17 correspond to original claims 10-16.

No subject-matter has been added.

Re Item II

2 The claimed priority appears to be valid.


Re Item V

3 Claim 16 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 39.1(iv) / 67.1(iv) PCT.

The patentability can be dependent upon the formulation of the claims. The EPO, for example, does not recognise as patentable claims to the use of a compound in medical treatment, but may allow claims to a product, in particular substances or compositions for use in a first or further medical treatment. Authorities other than the EPO, for example the USPTO might accept such claims as patentable.


4 Novelty (Article 33(2) PCT)

- 4.1 The present application is interpreted as referring to compounds of formula I (claim 1), ten specific compounds (claim 10), compositions comprising them (claims 12-13) and their medical use (claim 15) in the treatment of cancer, fibrotic diseases, etc. (claims 16-17).
- 4.2 D1 discloses the human glutaminyl cyclase (hQC) inhibitors SEN177 and SEN180 (structures depicted below). SEN177 is disclosed therein (Fig 11a of supplementary information) as having a IC_{50} on isolated hQC of 53 nM and on isolated QPCTL of 13 nM. SEN180 is disclosed therein (Fig 11a of supplementary information) as having a IC_{50} on hQC of 170 nM and on QPCTL of 58 nM. The compounds of claims 1 and 10 carry a central cyanophenyl group instead of the pyridine in SEN177 and SEN180.




- 4.3 D2 discloses QPCTL inhibitors of the general formula A-B-D-E, wherein A can be 4-methyl-1,2,4-triazol-3-yl, B can be heterocyclyl and E can be heteroaryl (claim 1), which shall include examples 1094 and 1095 (Formula (XIIa) on page 123 and table on page 125). Formula (A) of claim 1 of D2 seems to need correction, since not all the specific compounds of D2 seem to fall within its scope (ring D in claim 1 of D2 cannot be pyridine [but heteroaryl-amino instead]).

D2 does not disclose any biological data for examples 1094 or 1095. The presently claimed compounds seem to differ from - or at least be a novel selection of - the compounds of D2 due to their cyanophenyl-moiety.



- 4.4 D3 discloses QPCTL inhibitors of the general formula (A), which include compounds 3 and 6. M in Formula (A) cannot be unsubstituted 4-methyl-1,2,4-triazol-3-yl- as required in present claims 1 and 10.



- 4.5 Novelty over D1-D3 can therefore be acknowledged.
- 5 Inventive step (Article 33(3) PCT)
- 5.1 Any of D1-D3 can be regarded as representing the closest prior art.
- 5.2 The application contains data (tables 2 and 3 on pages 43-44), which show that the example compounds exhibit significantly higher inhibitory activity on QPCTL and QPCT than most of the structurally closest related compounds of the prior art (SEN177 and SEN180 of D1, compounds 1094 and 1095 of D2 and compound 3 of D3) and similarly high activity as compound 6 of D3.
- 5.3 The problem to be solved can therefore be seen in the provision/selection of compounds with high inhibitory activity on QPCTL and QPCT which could be useful in the treatment of diseases such as cancer, fibrotic diseases, neurodegenerative diseases, atherosclerosis, infectious diseases or chronic kidney diseases.
- 5.4 As a solution, the present application provides compounds of formula I according to claim 1 and ten specific compounds of claim 10. In view of the data discussed in paragraph 5.2 above, the problem can be regarded as being solved.
- 5.5 Nothing in D1-D3 indicated the high activity of the presently claimed compounds, i.e. the solution is not obvious. The most active compound of the prior art (compound 6 of D3) leads the skilled person away from the presently claimed compounds. Inventive step can therefore be acknowledged for the compounds of claim 1 and subject-matter referring to them.
- 6 Industrial Applicability
- Claims 1-17 are considered to be industrially applicable, they fulfil the requirements of Article 33(4) PCT.

Re Item VI

- 7 D4 discloses compounds 24, 25, 26, 27, 30, 33, 38, 39, 53, 56, 57, 59, 66-71, 76, 77, 94, 100, 130, the top left compound on page 65, the compounds in the 4th row of page 66, the compound top right in the schemes in paragraphs [00419], [00432] and [00447], the starting materials in paragraphs [00467] and [00477], and the second compounds in schemes in paragraphs [00522] and [00613], which fall within the scope of at least claims 1-6 and 9. Compositions comprising them and their medical use in the treatment of cancer, etc. has also been disclosed in D4. The compounds of claim 1 differ from these compounds due to their residue R¹ which must now be fluorine. The specific compounds of claim 10 have not been disclosed in D4. D4 is therefore not relevant for novelty.

Boehringer Ingelheim International GmbH · 55216 Ingelheim am Rhein

European Patent Office
Bob-van-Bentheim-Platz 1
80298 Munich

**Boehringer Ingelheim
International GmbH**
Global Patents

11 October 2024

International Patent Application No. PCT/EP2024/055766
Applicant: Boehringer Ingelheim International GmbH
Our Ref.: 01-3543-WO-1

Our reference: 01-3543-EP-1

Dr. Domnic MARTYRES
Phone +49 7351 54-3140
Fax +49 6132 72-4377
E-Mail patentmail@
boehringer-ingelheim.com

Pursuant to Article 31 PCT and Rules 54 and 54*bis* PCT, applicant herewith files a demand for international preliminary examination. The form PCT/IPEA/401 has been completed online.

Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Phone +49 6132 77-0
Fax +49 6132 72-0
www.boehringer-ingelheim.com

Concurrently, applicant submits a response to the written opinion of the international searching authority, and files amendments under Article 34 PCT.

Novelty

Specifically, prior art document D4 (WO 2024/020517 A1), as cited in the WO-ISA (Re Item VI, point 7) was filed before, but published after the filing date of the present application. It is therefore considered to be relevant only for novelty of the present claims.

In order to render the present claims novel over D4:

- Claim 1 has been amended wherein substituent R¹ has been restricted to F
- Claim 9 has been amended wherein several species have been deleted that correspond to R¹ is H according to Formula (I)
- New independent claim 10 has been introduced, that lists species contained in previous claim 9 that correspond to R¹ is H according to Formula (I) and are considered to be novel over D4
- The remaining claims have been renumbered

Board
Dr Paola Casarosa
Shashank Deshpande
Dr Sebastian Guntrum
Dr Lykke Hinsch Gylvin
Dr Torsten Mau
Torsten Rieck
Registered Office
Ingelheim am Rhein
Commercial Register Mainz
HR B 21063

Deutsche Bank AG
BIC: DEUTDE5MXXX
IBAN:
DE72 5507 0040 0012 2580 00

Inventive step

As acknowledged in the WO-ISA (Re Item V, point 5), the claims of the present invention are considered inventive over D1-D4. As discussed above, D4 is relevant for novelty only. However, if D4 were to be relevant for inventive step, claims 1 to 9 and dependent claims 11 to 17 would be considered inventive over D4 as well as any combination of D4 with D1 to D3 on account of, but not limited to, the F substituent these compounds possess, which corresponds to R¹ in formula (I). All examples in D1 to D4 have H as the corresponding R¹ substituent and thus offer no motivation at all to the skilled person to replace H at this position. Supportive data in the present application demonstrate that the present compounds have surprisingly inhibitory potency of QPCT and QPCTL as well as appropriate membrane permeability and efflux, thus being more viable for human use (page 8 lines 11-18). It is also true for claim 10 and dependent claims thereof, that although these compounds possess H as R¹ according to Formula (I), the combination of substituents and their regiochemistry with respect to the phenyl ring to which they are attached, are unique to the present compounds and do not follow any teaching in any of D1 to D4, neither through examples therein nor through a demonstrated relationship with membrane permeability. All of the present amended claims are thus submitted as being inventive over the prior art.

Basis in the description for the amendments is as follows:

- Claim 1: embodiment on page 14, lines 16-18
- Claim 9: Corresponds to examples 1, 2, 4, 5, 6, 9, 18, 19, 22, 24, 25, 27, 28, 29, 30, 33, 34, 35, 36 and 23
- New independent claim 10: is a selection from the list in previous claim 9 and corresponds to examples 8, 10, 11, 12, 13, 15, 17, 26, 31 and 32

Applicant attaches an amended claim set with visible changes and a clean version thereof in accordance with Rule 66.8 (c) PCT.

Applicant respectfully requests consideration of the amendments presently submitted, anticipating a positive IPER under Article 34(2)(c) PCT or otherwise a second written opinion under Rule 66.2 PCT.

For the applicant:

– *Authentication via EPO-ID with 2FA* –


Dr. Domnic MARTYRES
European Patent Attorney
GA 31039 (BI International GmbH)

Enclosure

Amended claims set as clean copy and with marked-up changes

WHAT IS CLAIMED

1. A compound of formula (I)



wherein

A is **A1a** which is a 5- or 6-membered mono-heteroaryl ring containing one or two heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur;

wherein at least one of the heteroatom members is nitrogen;

or **A** is **A1b** which is a 9- or 10-membered fused bicyclic-heteroaryl ring containing one to four heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur, wherein at least two of the heteroatom members is nitrogen;

R¹ is selected from the group **R1e**, consisting of F;

R² is selected from the group **R2a**, consisting of H, halo, hydroxy, C₁₋₆-alkyl, C₂₋₆-alkynyl, C₃₋₆-cycloalkyl, 1-methyl-C₃₋₆-cycloalkyl, F₁₋₉-fluoro-C₁₋₆-alkyl, HO-C₁₋₆-alkyl, C₁₋₆-alkyloxy, C₁₋₄-alkyl-O-H₂CH₂C-O-, C₃₋₆-cycloalkyloxy, C₃₋₆-cycloalkyl-H₂C-O-, F₁₋₉-fluoro-C₁₋₄-alkyloxy, C₁₋₆-alkyl-O-C(O)-, H₂N-C(O)- and C₁₋₆-alkyl-NH-C(O)-;

R³ is selected from the group **R3a**, consisting of H, C₁₋₄-alkyl, F₁₋₉-fluoro-C₁₋₄-alkyl and halo;

R⁴ is selected from the group **R4a**, consisting of halo, C₁₋₄-alkyl, C₃₋₆-cycloalkyl, -CN, C₁₋₆-alkyloxy, C₁₋₆-alkyl-O-C(O)-, F₁₋₉-fluoro-C₁₋₄-alkyl, F₁₋₉-fluoro-C₁₋₄-alkyloxy, C₃₋₆-cycloalkyloxy, C₃₋₆-cycloalkyl-H₂C-O-, benzyloxy, (HO)(H₃C)₂-C- and HO-C(H₃C)₂H₂CH₂C-O-;

or a salt thereof, particularly a pharmaceutically acceptable salt thereof.


10 **2.** The compound of formula (**I**) according to claim 1, wherein **A** is selected from the group **A5** consisting of pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, 2H-pyrazolo[3,4-b]pyridinyl and imidazo[1,2-a]pyrimidinyl; or a salt thereof.

15 **3.** The compound of formula (**I**) according to any of claims 1 to 2, wherein **R²** is **R2b**, consisting of H, halo, C₁₋₄-alkyl, C₃₋₄-cycloalkyl, F₁₋₉-fluoro-C₁₋₆-alkyl, 1-methyl-C₃₋₆-cycloalkyl, C₁₋₄-alkyloxy and C₃₋₄-cycloalkyloxy; or a salt thereof.

20 **4.** The compound of formula (**I**) according to any of claims 1 to 3, wherein **R⁴** is selected from the group **R4b**, consisting of halo, -CN, C₁₋₄-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkyloxy, C₁₋₆-alkyl-O-C(O)-, F₁₋₉-fluoro-C₁₋₄-alkyl, F₁₋₉-fluoro-C₁₋₄-alkyloxy, C₃₋₆-cycloalkyloxy, C₃₋₆-cycloalkyl-H₂C-O-, benzyloxy, (HO)(H₃C)₂-C- and HO-C(H₃C)₂H₂CH₂C-O-; or a salt thereof.

25


5. The compound of formula (**I**) according to any of claims 1 to 4 having formula (**1-c**)



(I-c)

or a salt thereof.


- 5 6. The compound of formula (I) according to any of claims 1 to 4 having formula (I-f)



(I-f)

or a salt thereof.

7. The compound of formula (I) according to any of claims 1 to 4 having formula (1-j)




(I-j)

or a salt thereof.

5


8. The compound of formula (I) according to any of claims 1 to 4 having formula (1-n)








(I-n)




or a salt thereof.

9. The compound of formula (I) according to claim 1, selected from the group consisting of











and

;

5 or a salt thereof.

10. A compound selected from the group consisting of





or a salt thereof.

- 5 **11.** A pharmaceutically acceptable salt of a compound according to one or more of claims 1 to 10.

- 12.** A pharmaceutical composition comprising one or more compounds according to one or more of claims 1 to 10, or pharmaceutically acceptable salts thereof, optionally together
10 with one or more inert carriers and/or diluents.

- 13.** A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 10, or pharmaceutically acceptable salts thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or dil-
15 uents.

14. The pharmaceutical composition according to claim 13 wherein the one or more additional therapeutic agents are selected from the group consisting of anticancer agents and antifibrotic agents.

5 **15.** The compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use as a medicament.

16. A method for the treatment of diseases, such as cancer or fibrotic diseases, and conditions associated with these diseases, in a patient in need thereof, the method being characterized in that one or more compounds according to one or more of claims 1 to 10 or pharmaceutically acceptable salts thereof are administered to the patient.

10 **17.** A compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use in a method for the treatment of cancer, fibrotic diseases, neuro-
15 degenerative diseases, atherosclerosis, infectious diseases, or chronic kidney diseases.

Bitte beachten Sie, dass angeführte Nichtpatentliteratur (wie z. B. wissenschaftliche oder technische Dokumente) je nach geltendem Recht dem Urheberrechtsschutz und/oder anderen Schutzarten für schriftliche Werke unterliegen könnte. Die Vervielfältigung urheberrechtlich geschützter Texte, ihre Verwendung in anderen elektronischen oder gedruckten Publikationen und ihre Weitergabe an Dritte ist ohne ausdrückliche Zustimmung des Rechtsinhabers nicht gestattet.

Bitte beachten Sie, dass das EPA Dokumente der Patentliteratur, die in Recherchen- und Prüfungsverfahren nach dem EPÜ und dem PCT angeführt sind, nicht mehr als Papierkopie per Post versendet. Anmelder, die nicht die Mailbox nutzen, können die betreffenden Dokumente über Espacenet (<https://worldwide.espacenet.com/>) einsehen.

Veuillez noter que les ouvrages de la littérature non-brevets qui sont cités, par exemple les documents scientifiques ou techniques, etc., peuvent être protégés par des droits d'auteur et/ou toute autre protection des écrits prévue par les législations applicables. Les textes ainsi protégés ne peuvent être reproduits ni utilisés dans d'autres publications électroniques ou imprimées, ni rediffusés sans l'autorisation expresse du titulaire du droit d'auteur.

Veuillez noter que l'OEB n'envoie plus par voie postale de copies papier de la littérature brevet citée dans les procédures de recherche et d'examen au titre de la CBE ou du PCT. Les demandeurs qui n'utilisent pas la Mailbox peuvent accéder à ces documents dans Espacenet (<https://worldwide.espacenet.com/>).

Please be aware that cited works of non-patent literature such as scientific or technical documents or the like may be subject to copyright protection and/or any other protection of written works as appropriate based on applicable laws. Copyrighted texts may not be copied or used in other electronic or printed publications or re-distributed without the express permission of the copyright holder.

Please note that the EPO no longer sends paper copies by post of patent literature cited in search and examination proceedings under the EPC and PCT. Applicants not using the Mailbox can access such documents via Espacenet (<https://worldwide.espacenet.com/>).

XS2006100103CF August 2024